- Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet
May 6, 2026 · zacks.com
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Analysts
Apr 23, 2026 · defenseworld.net
AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a
- Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
Apr 20, 2026 · zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf
Apr 15, 2026
AngioDynamics logo
Key Points
AngioDynamics completed a multi-year strategic reset with divestitures and innovation that left the company with no debt, significant cash and a revolver, while its MedTech segment has grown at a ~25% CAGR to nearly half of revenue and could exceed 50% next year. The company’s procedural platforms are gaining traction: the Auryon laser moved to the #3 market share in PAD, has a CE mark and is being evaluated for coronary use and possible IVL-like applications, while AngioVac and the new AlphaVac are expanding in the pulmonary embolism (PE) market with growing procedure volumes and supportive clinical data. In oncology, NanoKnife received FDA clearance (Dec 2024) and a CPT I code, sales are growing sequentially, and management pegs the focal prostate cancer TAM at about $1 billion in the U.S. (>$2 billion globally) while pursuing awareness, training and potential BPH research. Interested in AngioDynamics, Inc.? Here are five stocks we like better.
AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer used a presentation at Needham & Company’s 25th Annual Needham Healthcare Conference to outline the company’s multi-year transformation, highlight growth drivers in its MedTech segment, and discuss clinical and commercial plans for its three primary platforms: Auryon, AngioVac/AlphaVac, and NanoKnife.
Transformation and balance sheet focus
Clemmer said AngioDynamics began a strategic reset roughly five to six years ago, including three divestitures of product categories the company viewed as increasingly commoditized or less attractive long term. He said the company paired those moves with increased internal innovation and balance sheet strengthening.
→ 5 Space Stocks Already Climbing Ahead of the SpaceX IPO
“Today, we’re sitting here as a company with no debt on our books, significant cash position, a revolver if needed, but the ability to do what we want to do on our terms,” Clemmer said.
He emphasized that AngioDynamics now reports in two operating segments, with MedTech positioned as the future growth engine and MedDevice described as a more mature business that generates cash and EBITDA to support investment. Clemmer said MedTech has grown at a 25% compound annual growth rate over the period of the transformation and now represents nearly half of total revenue, up from less than 20% years ago. He suggested the segment could exceed 50% of revenue next year.
Auryon in peripheral arterial disease, with potential expansions
→ This New ETF Aims to Capitalize on Surging AI Memory Chip Demand
Clemmer highlighted the Auryon laser atherectomy platform in peripheral arterial disease (PAD), which AngioDynamics entered after a 2019 acquisition and launched commercially in September 2020. He said the device uses laser energy to disrupt calcified plaque and open diseased arteries, and can also treat in-stent restenosis (ISR).
Story Continues
In response to a question from Needham’s Mike Matson, Clemmer said about 10% of Auryon procedures involve ISR, and excluding those cases, utilization is roughly split between above-the-knee and below-the-knee interventions. “It’s about 50/50,” he said, adding that the mix reflects adoption of Auryon’s ability to treat hard calcification below the knee as well as above it.
→ GPU Prices Are Surging—3 Ways to Play the AI Chip Shortage
Clemmer said the company has moved from the sixth entrant in its category to the number-three share position and believes it can continue taking share. He also noted that Auryon now has a CE mark and that the company is working to expand use internationally.
Looking ahead, Clemmer said AngioDynamics sees a potential opportunity to move Auryon into the coronary arterial market. He cited a study in Italy sponsored by the Ministry of Health that, he said, generated data supporting safety and effectiveness. He added that the company is working with the FDA on study design and expects a PMA process that could take a few years.
Matson also asked about intravascular lithotripsy (IVL). Clemmer said the company has observed what customers described as an “IVL-like effect” from Auryon’s light-based energy, but he noted AngioDynamics is still evaluating the regulatory path, commercial opportunity, and whether design changes would be required. He said the company has not incorporated the IVL opportunity into its formal plans yet.
AngioVac and AlphaVac in the PE market
In venous disease, Clemmer focused on venous thromboembolism (VTE), including pulmonary embolism (PE). He said AngioDynamics views mechanical intervention as an increasingly important alternative to historical drug-based approaches and described the PE market as relatively early in penetration. He said AngioDynamics competes primarily with Inari and Penumbra in the space.
Clemmer described AngioVac as a foundational platform the company has had on the market for about 10 years, using a reinfusion circuit to extract clot or vegetation and reinfuse blood during complex procedures. He said the company intends to expand AngioVac’s addressable market over time.
He then described AlphaVac, calling it a purpose-built PE thrombectomy device developed after physicians requested a steerable, aspiration-controlled system paired with the “vortex funnel tip” design associated with AngioVac. Clemmer said the APEX trial supported PE labeling and that the study showed improved performance versus prior benchmarks, including pulling more clot and doing so faster, while demonstrating safety and efficacy.
Asked where AlphaVac is being used, Clemmer said it is currently labeled for PE and that PE remains the company’s primary focus, though he noted the device could be used over time in other settings such as clearing vegetation around the heart. He said procedure volumes are growing sequentially month to month, with an increasing mix in PE.
Matson also asked whether recent acquisitions of competitors have created market disruption. Clemmer said AngioDynamics has seen some change and disruption, but has remained focused on expanding its own commercial and clinical footprint. He added that recruitment has benefited as some experienced representatives show interest in joining AngioDynamics during industry transitions.
On clinical evidence, Clemmer said randomized trial activity in PE can have a “rising tide” effect by supporting the broader use of mechanical intervention rather than lytics. He added that AngioDynamics plans to run a study in Europe to help energize the market there and emphasized the role of real-world evidence in driving adoption.
NanoKnife launch in intermediate-risk prostate cancer
In oncology, Clemmer pointed to the NanoKnife system for focal therapy in intermediate-risk prostate cancer. He said 40% to 50% of men diagnosed with prostate cancer each year fall into that category, often characterized as Gleason 7, and argued NanoKnife can offer an option that treats diseased tissue while limiting side effects associated with radical prostatectomy or some other treatments.
Clemmer said NanoKnife received FDA clearance in December 2024 and obtained a CPT I code effective January 1 of this year. He said the device uses electrical pulses to create “nano-sized particle holes” in tissue, leading tumors to die naturally while limiting disruption to surrounding functions. He said sales are growing sequentially and framed the market opportunity as “nearly a billion-dollar U.S. TAM and over $2 billion global TAM” for this treatment approach.
He referenced the PRESERVE study as supporting NanoKnife’s clinical profile, emphasizing preservation of function and the ability to maintain future treatment options if needed. Clemmer said the key commercial challenge is increasing awareness and training among urologists and educating newly diagnosed patients. He also noted marketing efforts, including being recognized by TIME in 2025 as a top invention of the year and co-marketing with AARP, alongside social media campaigns.
Matson asked about benign prostatic hyperplasia (BPH). Clemmer said AngioDynamics is investigating NanoKnife’s potential in BPH based on physician feedback indicating prostate shrinkage and symptom improvement following prostate cancer treatment. He said the company is evaluating the regulatory pathway and study design and believes additional R&D may not be necessary, though he emphasized the work is still early.
Financial update and portfolio considerations
Clemmer said AngioDynamics’ three highlighted MedTech platforms are accretive to corporate gross margins and could help lift margins as they grow. He also cited the company’s recently reported fiscal third-quarter results (quarter ended February 28), saying AngioDynamics “hit or beat” expectations and raised guidance for the third time this year. He said MedTech grew nearly 20% and MedDevice grew “above flat,” which he characterized as a win.
On portfolio management, Clemmer said the company remains open to additional rationalization within MedDevice to make AngioDynamics “closer to a pure play,” though he credited the existing team for operating the segment efficiently. On M&A, he said AngioDynamics would consider opportunities, but any deal would likely be a smaller adjacency given the company’s focus on expanding its current platforms and its view that those platforms already provide significant addressable-market expansion opportunities.
About AngioDynamics (NASDAQ:ANGO)
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
The article "AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf" was originally published by MarketBeat.
View Comments
- AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Apr 10, 2026 · zacks.com
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- AngioDynamics (ANGO) Upgraded to Buy: Here's Why
Apr 8, 2026 · zacks.com
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
Apr 6, 2026
AngioDynamics, Inc. ANGO reported an adjusted loss per share of 7 cents for third-quarter fiscal 2026, narrower than the year-ago quarter’s adjusted loss per share of 8 cents and the Zacks Consensus Estimate of a loss of 11 cents.
GAAP loss per share was 19 cents, wider than the year-ago period’s 11 cents.
ANGO’s Revenue Details
Revenues in the fiscal third quarter totaled $78.4 million, up 8.9% year over year both on a reported and pro forma basis. The top line outpaced the Zacks Consensus Estimate by 1.4%.
The company continued to see strong contributions from its Med Tech (which includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform) and Med Device businesses during the quarter.
Shares of this company gained nearly 1.1% in today’s pre-market trading.
AngioDynamics’ Geographical Analysis
In the quarter under review, U.S. net revenues totaled $67.3 million, up 9.7% year over year both on a reported and pro forma basis. This figure compares to our U.S. net revenues’ fiscal third-quarter projection of $65.7 million.
International revenues came in at $11.1 million, up 4.5% from the year-ago quarter, both on a reported and pro forma basis. This figure compares to our fiscal third-quarter International revenues’ projection of $11.1 million.
ANGO’s Segmental Analysis
AngioDynamics derives revenues from two businesses — Med Tech and Med Device.
The Med Tech business’ net sales in the fiscal third quarter were $37.3 million, reflecting an uptick of 18.9% year over year both on a reported and pro forma basis. This figure compares to our fiscal third-quarter Med Tech business’ net sales projection of $36.4 million.
The rise was primarily on the back of increased net sales of Auryon, amounting to $16.3 million (up 17.9% year over year), Mechanical Thrombectomy revenues (which includes AngioVac and AlphaVac) of $11.5 million (up 17.9% year over year) and NanoKnife sales of $7.6 million (up 21% year over year). In the quarter, AngioVac revenues were $7.2 million (up 5% year over year) and AlphaVac revenues were $4.4 million (up 47.4% year over year). Total NanoKnife revenues included 20% growth in probes and 24.9% growth in capital sales.
Med Device revenues in the fiscal third quarter grossed $41.1 million (up 1.2% from the year-ago period) and $40.7 million (up 1.1%) on a reported and pro forma basis, respectively. This figure compares to our fiscal third-quarter Med Device business’ net sales projection of $40.4 million.
AngioDynamics, Inc. Price, Consensus and EPS SurpriseAngioDynamics, Inc. Price, Consensus and EPS Surprise
AngioDynamics, Inc. price-consensus-eps-surprise-chart | AngioDynamics, Inc. Quote
Story Continues
AngioDynamics’ Margin Analysis
In the quarter under review, AngioDynamics’ pro forma gross profit rose 6.7% to $41.5 million. However, the pro forma gross margin contracted 107 basis points to 52.9%. We had projected a pro forma gross margin of 54.9% for third-quarter fiscal 2026.
Sales and marketing expenses on a pro forma basis increased 7.6% to $27.4 million year over year. Research and development expenses on a pro forma basis increased 2.5% year over year to $7.1 million, whereas general and administrative expenses on a pro forma basis increased 2.2% to $10.7 million. On a pro forma basis, adjusted operating expenses of $45.2 million increased 5.4% year over year.
The adjusted operating loss on a pro forma basis totaled $3.8 million compared with the prior-year quarter’s loss of $4 million.
ANGO’s Cash Position
AngioDynamics exited third-quarter fiscal 2026 with cash and cash equivalents of $37.8 million compared with $41.6 million at the fiscal second-quarter-end.
The company ended the quarter with no debt on its balance sheet.
Cumulative net cash used in operating activities at the end of third-quarter fiscal 2026 was $14.4 million compared with $28.9 million a year ago.
AngioDynamics’ FY26 Guidance
AngioDynamics has revised its guidance for fiscal 2026.
The company now expects its net sales to be in the range of $313.5 million-$315.5 million, up from the prior outlook of revenues between $312 million and $314 million. The Zacks Consensus Estimate is currently pegged at $313.2 million.
AngioDynamics now expects its Med Tech revenue growth to be in the range of 15%-17%, up from the prior growth projections of 14%-16% from the comparable fiscal 2025 period.
Med Device revenue growth is now projected to be approximately 1% compared with the earlier growth projection of 0%-1% from the comparable fiscal 2025 period.
The adjusted loss per share is now projected to be between 30 and 23 cents, narrowed from the earlier projections of 33 and 23 cents. The Zacks Consensus Estimate is currently pegged at a loss of 27 cents per share.
Our Take on ANGO
AngioDynamics exited the third quarter of fiscal 2026 with narrower-than-expected adjusted loss per share and better-than-expected revenues. The uptick in overall revenues and geographical revenues, both on a reported and pro forma basis, looked promising. The robust performance of both segments was also impressive. Robust Auryon, AngioVac, AlphaVac and NanoKnife sales were also recorded during the quarter.
Per management, ANGO’s mechanical thrombectomy portfolio exhibited strong performance during the quarter as commercial adoption continued to build with both AlphaVac and AngioVac.
However, dismal bottom-line results were disappointing. The pro-forma gross margin contraction does not bode well.
AngioDynamics’ Zacks Rank & Key Picks
ANGO currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space that are expected to report earnings soon are Globus Medical, Inc. GMED, DaVita Inc. DVA and GE HealthCare Technologies Inc. GEHC.
The Zacks Consensus Estimate for Globus Medical’s first-quarter 2026 adjusted earnings per share (EPS) is currently pegged at 92 cents. The consensus estimate for revenues is pegged at $728.9 million. GMED currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical has an estimated long-term growth rate of 9.6%. GMED’s earnings yield of 5.1% compares favorably with the industry’s negative yield.
DaVita currently has a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $2.41. The same for revenues is pegged at $3.30 billion.
DaVita has an estimated long-term growth rate of 20.2%. DVA’s earnings yield of 9.7% compares favorably with the industry’s 5.7%.
GE HealthCare currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.07. The same for its revenues is pegged at $5.06 billion.
GE HealthCare has an estimated long-term growth rate of 9.1%. GEHC’s earnings yield of 7.1% compares favorably with the industry’s 2.4%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
Apr 6, 2026 · zacks.com
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.
- AngioDynamics Growing, But With More Noise Than The Street Likes
Apr 5, 2026 · seekingalpha.com
AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.
- AngioDynamics Q3 Earnings Call Highlights
Apr 4, 2026 · defenseworld.net
AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 third-quarter results that management described as "strong across the board," highlighted by faster growth in its MedTech segment and improved adjusted EBITDA. The company also raised its full-year outlook for net sales and adjusted EBITDA for the third consecutive quarter, citing continued execution across its core platforms. Quarterly results show
